"Why Quarterly Reviews Break Long-Cycle Pipelines: The Two-Clock Rule"

What you'll take away

• Why 90 days is enough time to inspect the work, and often not enough time to expect closed revenue
• The separate clocks behind search, the sales cycle, and customer acquisition payback
• What to review each month, at six months, and when a cohort has had time to close
• A board ready way to explain the difference without asking anyone to wait and see

Your board asks what happened to third quarter pipeline.

Marketing spent $180,000. There is one deal in stage 3. No new closed revenue. The agency brought graphs, rankings, impressions, and a long explanation. You defended the spend, and you could feel the question under it: what did we get for the money?

Here is the honest answer in that room. You are judging a system whose buying cycle runs 12 to 24 months on a 90 day timer. That 12 to 24 months is the cycle you are being asked to defend. It is not a census of every healthcare sale.

That does not mean marketing should get a blank check. It means the review needs to match the work. At 90 days, you should know whether the program is being executed well and whether the first cohort is moving. You often cannot know yet whether that cohort will produce revenue.

The problem is not the quarterly review. The problem is treating a quarterly review as a final revenue verdict.

The clocks behind marketing spend

A growth program can be working well and still have no closed revenue after 90 days. That is especially true for healthcare, biotech, medtech, and enterprise software companies, where the purchase involves a committee, procurement, compliance review, technical validation, and budget timing.

Three clocks matter.

The search clock

Search rarely behaves like paid media. You can launch a paid campaign today and see traffic tomorrow. Organic visibility takes longer because search engines have to discover, index, interpret, test, and eventually trust new pages.

Ahrefs found that only 1.74 percent of newly published pages reached Google's top 10 within a year, down from 5.7 percent in its 2017 study (Ahrefs, May 2025). Google's starter guide says some changes can take a few hours and others several months, and that you generally want to wait a few weeks before judging whether the work helped in search results (Google SEO Starter Guide).

That does not mean you should see nothing in the first 90 days. You should see pages published and indexed, technical problems resolved, search impressions growing, a wider set of relevant queries in Search Console, and early movement on longer, lower competition terms.

What you should not expect is that every priority commercial keyword will be in the top 10, producing qualified pipeline, three months after the work begins.

At 12 months, the standard is much higher. The program should show material progress against the agreed target queries, meaningful visibility on searches that are not your brand name, and evidence that organic traffic is contributing to qualified demand. If it does not, the strategy needs a serious reset, or the engagement should end.

The sales cycle clock

The sales cycle is the time it takes a prospect to move from a meaningful conversation to a signed deal. In a complex B2B market, that timeline is usually set by the customer, not by the marketing calendar.

The number varies widely by deal size, buying process, and category. Healthcare and life sciences often take longer. Apollo's biotech guide cites a typical 12 to 18 month sales cycle (Apollo, Biotech Sales). That page does not show the study behind the range. Treat it as a vendor guide, not your cycle. The more regulated, technical, and expensive the purchase, the longer it often takes to reach agreement.

A prospect who first engaged in March may not become a customer until the following March. A June board review should ask whether that prospect became qualified, entered the right sales process, and moved through the expected early stages.

It should not ask why March marketing has not already created June revenue.

The payback clock

Payback is different from the sales cycle. The sales cycle measures how long it takes to close a customer. Payback measures how long it takes to recover the cost of acquiring that customer after the sale.

Aleph's 2026 benchmark, based on full year 2025 results from 342 SaaS and AI software companies, puts median payback at 16 months. The top quartile pays back acquisition cost in six months or less. The bottom quartile takes 24 months or more (Aleph, 2026). This is a software sample. It is not a healthcare census.

Payback is not a 90 day campaign metric. It is a measure of whether the growth model is economically sound. Assess it by customer cohort, using real acquisition cost, gross margin, retention, and expansion.

A company can create healthy pipeline in a quarter, close a deal six or 12 months later, and still need more time to recover the cost of winning that customer. Those are three separate events. A useful board review does not collapse them into one number.

The comparison with a marketing hire

Most companies do not hire a marketing leader on Monday and ask for a final revenue verdict 90 days later.

They expect that person to learn the market, assess the pipeline, establish measurement, fix broken systems, align sales and marketing, build a plan, and begin the work. The same should be true of an outside partner doing comparable growth work, even when the engagement is structured differently.

Spencer Stuart reports that average tenure among chief marketing officers at S&P 500 companies is 4.1 years, compared with 5.0 years for C suite roles overall (Spencer Stuart, CMO Tenure 2026). Its 2025 Fortune 500 study reported average tenure of 4.3 years (Spencer Stuart, CMO Tenure Study 2025). Those figures do not mean a marketing leader gets years without accountability. They do show that companies already treat this work as something one quarter of closed revenue cannot fairly judge.

The answer is not to avoid accountability. It is to define the right accountability at the right time.

Use two clocks, not one

A serious growth program needs two review rhythms at the same time.

The first is a monthly operating review. Its job is to find mechanical failures before they become expensive. The second is a cohort and revenue review, timed to the company's actual sales cycle.

Every 30 days: inspect the machine

At the monthly review, ask whether the program is producing the inputs and early evidence a later revenue outcome needs.

Review a short set of indicators:

• Technical search health, tracking, CRM attribution, and lead routing are working
• Priority pages and campaigns are live, indexed, and reaching the intended audience
• Search impressions, paid reach, click quality, and coverage of the target queries are moving in the right direction
• Cost per qualified lead is inside an agreed range by channel
• Leads are getting a timely first response and a real disposition from sales
• The earliest cohort is moving from inquiry to a qualified conversation, an opportunity, and the next expected stage

The point is not to celebrate activity. Publishing, buying clicks, and generating form fills are not outcomes on their own.

The question is whether the system is functioning, whether the audience is responding, and whether that response is becoming qualified pipeline.

If cost per qualified lead is five times the target for two months running, that is a problem. If leads wait four days for a sales response, that is a problem. If pages are not indexing, attribution is broken, or the campaign is optimizing toward low quality conversions, those are problems.

Fix them quickly. Do not wait until month 12 to discover them.

At six months: judge pipeline quality

At six months, the first cohort should give a meaningful read on pipeline quality for many B2B programs. That is the time to ask whether marketing is creating the right kind of demand, and whether that demand is moving through the stages at a reasonable rate.

Review:

• Qualified pipeline created, by source and campaign
• Conversion from inquiry to qualified lead, qualified lead to opportunity, and opportunity to later sales stages
• Pipeline value, stage distribution, and fit with the accounts you meant to reach
• Sales acceptance and follow up quality
• Cohort performance compared with similar historical opportunities

That last point matters most.

Do not compare a new March cohort only with a revenue target. Compare it with prior closed won cohorts at the same age. If past enterprise healthcare opportunities typically reach stage 2 within three months and close around month 10, the question at month three is whether this cohort is reaching stage 2 at a comparable rate.

That is a real performance test. It is more useful than asking why a deal that usually takes 10 months has not closed in three.

At revenue maturity: judge the business result

Revenue should always be visible. It should not be hidden from a board deck for 12 months.

Closed revenue should not become the only pass or fail verdict until the relevant marketing cohort has had a reasonable chance to move through the company's observed sales cycle.

For many complex B2B companies, that review happens at 12 months. For an 18 month motion, it may happen later. Use your own CRM to define the date:

• Median time from first meaningful engagement to a qualified opportunity
• Median time from opportunity to close
• Stage conversion rates and win rate
• Average contract value and gross margin
• Acquisition cost and payback
• Retention and expansion from customers acquired during the period

External benchmarks are useful context. Your CRM is the evidence that matters.

Put the dates in the agreement

The cleanest way to avoid the 90 day argument is to agree on the review cadence before work begins.

A sound engagement should define three things:

1. What must be working by day 30, day 60, and day 90.
2. What pipeline and stage progression evidence should exist by month six.
3. When a cohort will be mature enough for a fair review of closed revenue and payback.

This does not protect a bad agency. It makes weak performance easier to identify.

If execution is weak, early demand is poor, and the fixes do not improve results by day 90, that is a real signal. The client should change the plan, change the team, or stop spending.

If the program is functioning, qualified opportunities are progressing, and the sales cycle has historically taken 12 months, calling the program a failure at month three is not financial discipline. It is the wrong question.

The board slide

For the next board meeting, use this:

Marketing runs on two clocks. Every 30 days, we review operating health and early demand: visibility on the target queries, campaign quality, cost per qualified lead, response time, lead routing, and progression of the newest cohort. Those indicators are currently [green, yellow, or red], and the specific actions in progress are [name them].

We review pipeline quality and stage conversion at six months. We review closed revenue, acquisition cost, and payback once the relevant cohort has had time to move through our observed sales cycle of [N] months. The first fair revenue read on this quarter's spend is [date]. Until then, the question is not whether revenue has already appeared. The question is whether the cohort is progressing as it should.

That is not a request for patience. It is a measurement system.

The honest limit

The two clock rule does not excuse weak work.

A program can fail early. It can fail because the audience is wrong, the offer is unclear, the content is weak, the targeting is poor, the lead handoff is broken, or the sales team does not follow up. Those failures should be visible in the first 30 to 90 days.

The rule is simply this.

Do not confuse a monthly operating check with a final revenue verdict.

Inspect the machine every month. Judge the pipeline as the cohort matures. Judge revenue and payback when the sales cycle and the economics have had time to produce an answer.

That is how you hold marketing accountable without ending work that has not yet had time to work.

If you are the founder or chief operating officer of a Series A to C healthcare, biotech, medtech, or healthcare software company and the last board meeting asked a hard question about marketing spend, [book a pipeline call](/contact). Send the marketing slide from that deck and the sales cycle you report. In about ten minutes I'll tell you whether the review cadence matches the buying cycle, and what to change. Sometimes the honest answer is that you're already fine, and we're happy to say so and hand you back your afternoon.